Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.

Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, Hagel C, Friedrich RE, Adam G, Mautner VF.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):685-92. doi: 10.1007/s00259-012-2314-6. Epub 2012 Dec 12.

PMID:
23232507
2.

18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Salamon J, Veldhoen S, Apostolova I, Bannas P, Yamamura J, Herrmann J, Friedrich RE, Adam G, Mautner VF, Derlin T.

Eur Radiol. 2014 Feb;24(2):405-12. doi: 10.1007/s00330-013-3020-x. Epub 2013 Oct 5.

PMID:
24097302
3.

Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Derlin T, Tornquist K, Münster S, Apostolova I, Hagel C, Friedrich RE, Wedegärtner U, Mautner VF.

Clin Nucl Med. 2013 Jan;38(1):e19-25. doi: 10.1097/RLU.0b013e318266ce84.

PMID:
23242059
4.
5.

[18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1.

Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ.

Eur J Nucl Med Mol Imaging. 2009 May;36(5):751-7. doi: 10.1007/s00259-008-1038-0. Epub 2009 Jan 14.

PMID:
19142634
6.
7.

Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT.

Salamon J, Papp L, Tóth Z, Laqmani A, Apostolova I, Adam G, Mautner VF, Derlin T.

PLoS One. 2015 Dec 1;10(12):e0143305. doi: 10.1371/journal.pone.0143305. eCollection 2015.

8.
9.

Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.

Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A.

Neurosurgery. 2009 Oct;65(4 Suppl):A160-70. doi: 10.1227/01.NEU.0000337597.18599.D3.

PMID:
19927062
10.

Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign.

Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC.

Cancer. 2010 Jan 15;116(2):451-8. doi: 10.1002/cncr.24755. Erratum in: Cancer. 2010 Feb 1;116(3):775.

11.

Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.

Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M, Mautner VF.

Eur J Nucl Med Mol Imaging. 2006 Apr;33(4):428-32. Epub 2006 Jan 11.

PMID:
16404595
12.

Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.

Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR.

Clin Nucl Med. 2014 May;39(5):e301-7. doi: 10.1097/RLU.0b013e3182a757d3.

PMID:
24152623
13.

Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1.

Combemale P, Valeyrie-Allanore L, Giammarile F, Pinson S, Guillot B, Goulart DM, Wolkenstein P, Blay JY, Mognetti T.

PLoS One. 2014 Feb 6;9(2):e85954. doi: 10.1371/journal.pone.0085954. eCollection 2014.

14.

Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.

Salamon J, Mautner VF, Adam G, Derlin T.

Rofo. 2015 Dec;187(12):1084-92. doi: 10.1055/s-0035-1553505. Epub 2015 Sep 2. Review.

15.

Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.

Moharir M, London K, Howman-Giles R, North K.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1309-17. doi: 10.1007/s00259-010-1386-4. Epub 2010 Feb 24.

PMID:
20179923
16.

Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours.

Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N, Mechtersheimer section sign G, Lehnert T.

Eur J Surg Oncol. 2003 Aug;29(6):536-41.

PMID:
12875862
17.

Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients.

Brahmi M, Thiesse P, Ranchere D, Mognetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P.

PLoS One. 2015 Oct 7;10(10):e0138386. doi: 10.1371/journal.pone.0138386. eCollection 2015.

18.

[18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.

Tsai LL, Drubach L, Fahey F, Irons M, Voss S, Ullrich NJ.

J Neurooncol. 2012 Jul;108(3):469-75. doi: 10.1007/s11060-012-0840-5. Epub 2012 Mar 11.

PMID:
22407214
19.

Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?

Berzaczy D, Mayerhoefer ME, Azizi AA, Haug AR, Senn D, Beitzke D, Weber M, Traub-Weidinger T.

PLoS One. 2017 Dec 5;12(12):e0189093. doi: 10.1371/journal.pone.0189093. eCollection 2017.

20.

Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.

Dong X, Wu P, Sun X, Li W, Wan H, Yu J, Xing L.

J Med Imaging Radiat Oncol. 2015 Jun;59(3):338-45. doi: 10.1111/1754-9485.12289. Epub 2015 Feb 23.

PMID:
25708154

Supplemental Content

Support Center